Bartosz Chmielowski, MD, PhD, health sciences clinical professor, medicine, Division of Hematology-Oncology, Sarcoma and Connective Tissue Medical Oncology, UCLA Health, discusses the rationale for investigating oncolytic viruses in melanoma.
Health Professionals
Study Reveals Immune Checkpoint Inhibitor Treatment and Monitoring Practices Post-Remission
Post treatment discontinuation, most centers conduct imaging every 3 months during the first year of remission.
Recurrence, mortality rates better in nevus-associated vs. de novo acral melanoma
Five-year recurrence-free survival was 55.1% with nevus-associated acral melanoma (NAAM) vs. 42.3% with de novo acral melanoma (DNAM).
RP1 Combination Shows Response, Safety in Advanced Melanoma
Vusolimogene oderparepvec plus nivolumab showed responses and a favorable safety profile in advanced melanoma post-anti–PD-1 therapy, per phase 2 IGNYTE trial data.